Cargando…

Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements

Cholangiocarcinoma (CCA) is an aggressive and diverse malignancy with a poor prognosis. Related to a typical indolent course of progression, most cases of CCA are metastatic or locally advanced at the time of presentation. For patients with nonresectable tumors or metastatic disease, the mainstay of...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, Kathryn, Anwar, Ahmed I, Jin, Kevin, Bollich, Victoria, Kelkar, Rucha A, Talbot, Norris C, Klapper, Rachel J, Ahmadzadeh, Shahab, Viswanath, Omar, Varrassi, Giustino, Shekoohi, Sahar, Kaye, Alan D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634393/ https://www.ncbi.nlm.nih.gov/pubmed/37954763 http://dx.doi.org/10.7759/cureus.46792

Ejemplares similares

Topical Cocaine Hydrochloride Nasal Solution: Anesthetic and Surgical Considerations
por: Lutfallah, Salim C, et al.
Publicado: (2023)

Lyme Disease and Post-treatment Lyme Disease Syndrome: Current and Developing Treatment Options
por: Talbot, Norris C, et al.
Publicado: (2023)

Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review
por: Bocklud, Brooke E, et al.
Publicado: (2023)

Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options
por: Spillers, Noah J, et al.
Publicado: (2023)

Overview of Median Arcuate Ligament Syndrome: A Narrative Review
por: Upshaw, Will, et al.
Publicado: (2023)

Vigabatrin (Sabril) for the Treatment of Refractory Complex Focal Seizures in Adults: Pharmacologic and Clinical Considerations
por: Gatson, Taylor N, et al.
Publicado: (2023)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Oral Therapeutics Post Menopausal Osteoporosis
por: Schroeder, Ryan J, et al.
Publicado: (2023)

Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
por: Yu, James, et al.
Publicado: (2021)

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
por: Lassman, Andrew B., et al.
Publicado: (2022)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020)

Safety and Effectiveness of Tofacitinib in Treating Polyarticular Course Juvenile Idiopathic Arthritis
por: Jones, Nicholas T, et al.
Publicado: (2023)

Correction to: Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

Telemedicine, E-Health, and Multi-Agent Systems for Chronic Pain Management
por: Ahmed Kamal, Manar, et al.
Publicado: (2023)

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
por: Demuynck, Benoit, et al.
Publicado: (2020)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies
por: Savarirayan, Ravi, et al.
Publicado: (2022)

Chromosomal Study of Couples with the History of Recurrent Spontaneous Abortions with Diagnosed Blightded Ovum
por: Shekoohi, Sahar, et al.
Publicado: (2013)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

OR21-05 Low-dose Infigratinib, An Oral Selective Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, Demonstrates Activity In Murine Models Of Achondroplasia And Hypochondroplasia
por: Muslimova, Elena, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology
por: Sinnathamby, Evan S., et al.
Publicado: (2023)

The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review
por: Neuchat, Elisa E., et al.
Publicado: (2023)

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs
por: Daniel, Charles P., et al.
Publicado: (2023)

Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma
por: Huynh, Hung, et al.
Publicado: (2019)

Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype
por: Zou, Yining, et al.
Publicado: (2023)

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
por: Wang, Jing, et al.
Publicado: (2020)

FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
por: Saborowski, Anna, et al.
Publicado: (2020)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Occupational burnout syndrome and post-traumatic stress among healthcare professionals during the novel coronavirus disease 2019 (COVID-19) pandemic
por: Raudenská, Jaroslava, et al.
Publicado: (2020)

Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice
por: Roberts, Logan T., et al.
Publicado: (2022)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
por: McIntosh, Sydney Moore, et al.
Publicado: (2023)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
por: Shi, Guo‐Ming, et al.
Publicado: (2022)

FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
por: Sridharan, Vishwajith, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fo15h158vsk44fqk9fv5n55fvg